APA (7th ed.) Citation

E, G., M, L., H, D., E, G., JS, L., R, S., . . . GJ, P. (2013). Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Current pharmaceutical design, 19(5), 927.

Chicago Style (17th ed.) Citation

E, Giovannetti, et al. "Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-small-cell-lung Cancer (NSCLC) Cells." Current Pharmaceutical Design 19, no. 5 (2013): 927.

MLA (9th ed.) Citation

E, Giovannetti, et al. "Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-small-cell-lung Cancer (NSCLC) Cells." Current Pharmaceutical Design, vol. 19, no. 5, 2013, p. 927.